BPC-157 mcg vs mg: Dosing Units Explained for BPC-157, TB-500, and GHK-Cu

Why the mcg vs mg Distinction Matters for BPC-157

Confusing micrograms and milligrams is the single most common dosing error with BPC-157. One milligram equals 1,000 micrograms. A prescriber who writes "0.5 mg" and a compounder who reads "0.5 mcg" produce a solution 1,000 times weaker than intended. That difference is not trivial when the biologically active window in rodent studies sits between 10 and 200 mcg/kg.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids, first isolated from human gastric juice. Research published in the Journal of Physiology and Pharmacology by Sikiric et al. identified the sequence and its cytoprotective properties, with multiple follow-up papers cataloguing effects on tendon-to-bone healing, gut mucosal integrity, and nitric oxide modulation (PubMed: Sikiric 2018). All published dose-response data express BPC-157 in micrograms per kilogram or, in some oral administration studies, micrograms per milliliter of drinking water.

A 2019 paper in Current Neuropharmacology summarizing BPC-157 CNS research used subcutaneous doses of 10 mcg/kg in rat models, equivalent to roughly 14 mcg in a 280-gram rat (PubMed). Scaling allometrically to an 80 kg adult using a standard rodent-to-human conversion factor of 6.2 yields approximately 129 mcg. Most clinical-use protocols in the gray-market peptide literature fall between 200 and 500 mcg per injection, which is consistent with that extrapolation while applying a modest upward adjustment for the lower metabolic rate in humans.

The practical conversion table:

| Written Dose | Actual Quantity | |---|---| | 200 mcg | 0.2 mg | | 500 mcg | 0.5 mg | | 1 to 000 mcg | 1.0 mg (maximum cited in most protocols) |

Always confirm with your compounding pharmacy whether your vial label reads mcg or mg before drawing volume.

How to Calculate a BPC-157 Injection Dose

The standard starting point for subcutaneous or intramuscular BPC-157 is 200 to 300 mcg once or twice daily. Research on tendon and ligament healing in rat Achilles-tendon transection models used 10 mcg/kg intraperitoneally once daily for 14 days and produced statistically significant improvements in breaking strength at 14 days (P<0.01 vs. vehicle) (PubMed: Chang 2011).

Most compounded BPC-157 arrives as a lyophilized powder in a 5 mg vial. Reconstitution steps:

1. Add 2.5 mL bacteriostatic water to a 5 mg vial. Final concentration: 2 mg/mL (2 to 000 mcg/mL).
2. For a 250 mcg dose, draw 0.125 mL (12.5 units on a 100-unit insulin syringe).
3. For a 500 mcg dose, draw 0.25 mL (25 units).

Injection site proximity to the area of injury is a debated topic. Animal studies on gut healing use intraperitoneal routes, while musculoskeletal studies use both systemic (IP, subcutaneous) and local (intramuscular near tendon) administration. A 2013 paper in the Journal of Orthopaedic Research found that both local and systemic BPC-157 accelerated medial collateral ligament healing in rats at 10 mcg/kg (PubMed). No human randomized controlled trial has compared injection sites directly.

Reconstituted peptide should be refrigerated at 2 to 8 degrees Celsius and used within 28 days. Freeze-thaw cycles degrade the peptide; avoid repeated freezing of the reconstituted solution (PubMed: peptide stability).

BPC-157 Oral vs. Injectable Dosing

Oral BPC-157 administration has been studied in rat models of colitis, aspirin-induced gastric lesions, and fistula repair. Doses in drinking water range from 10 ng/kg (nanograms) to 10 mcg/kg, which is 10 to 10,000 times lower than injectable doses and still produce measurable mucosal healing in those models (PubMed: Sikiric 2016).

If the goal is systemic musculoskeletal or tendon repair, oral bioavailability is a limiting factor. BPC-157 is a peptide and subject to proteolytic degradation in the GI tract. The degree of that degradation in humans has not been formally quantified in published pharmacokinetic studies. Animal data suggest some fraction survives transit and reaches systemic circulation, but the effective systemic dose from oral delivery is lower and less predictable than from subcutaneous injection.

For gut-specific indications (gastric ulcer, colitis, leaky gut in preclinical models), oral delivery is appropriate and the literature supports lower doses of 100 to 250 mcg per day. For musculoskeletal applications, subcutaneous injection of 200 to 500 mcg once or twice daily is the format most consistent with the preclinical dose-response data (PubMed: Sikiric 2014).

TB-500 Dosing: mg Is the Correct Unit

TB-500 is a synthetic fragment of Thymosin Beta-4 (TB4), specifically the actin-binding sequence LKKTETQ. TB-500 is dosed in milligrams, not micrograms. This is the key unit difference from BPC-157.

Standard loading and maintenance dosing used in research and reported in clinical peptide literature:

• Loading phase (weeks 1 to 6): 4 to 5 mg per week, divided into two subcutaneous injections of 2 to 2.5 mg each.
• Maintenance phase (weeks 7 onward): 2 to 2.5 mg per week as a single injection.

A 2010 Phase II trial in the Journal of the American College of Cardiology evaluated Thymosin Beta-4 (the parent peptide, not the fragment) in 72 patients with pressure ulcers. Doses ranged from 0.03 to 0.1 mg/kg administered subcutaneously twice weekly, with the highest dose corresponding to 8 mg per week in an 80 kg patient (PubMed). Skin healing scores improved significantly at the 0.1 mg/kg dose (P<0.05 vs. placebo).

Thymosin Beta-4 also showed cardioprotective properties in a 2010 JACC study by Smart et al., who noted that "Thymosin Beta-4 promoted neovascularization and cardiomyocyte survival in ischemic myocardium" in murine models (PubMed: Smart 2010). The TB-500 fragment shares the actin-binding domain but is a shorter sequence; whether it replicates the full peptide's cardiovascular effects in humans remains untested.

Reconstitution for TB-500: a common 10 mg vial dissolved in 2 mL bacteriostatic water yields 5 mg/mL. A 2 mg dose requires drawing 0.4 mL (40 units on an insulin syringe).

TB-500 is injected subcutaneously, typically in the abdomen. Intramuscular injection near an injured site is also used in practice, but no controlled head-to-head comparison of injection routes exists in peer-reviewed literature.

GHK-Cu Topical Dosing

GHK-Cu (copper peptide GHK-Cu, glycine-histidine-lysine-copper) is a naturally occurring tripeptide-copper complex found in human plasma. Plasma concentrations decline from roughly 200 ng/mL at age 20 to below 80 ng/mL by age 60, and this decline correlates with reduced skin renewal rates in observational data (PubMed: Pickart 2015).

For topical skin applications, GHK-Cu is formulated at concentrations of 1 to 5 mg/mL (0.1 to 0.5 percent w/v). A 2015 review in the Journal of Aging Research by Pickart and Margolina concluded that "GHK-Cu stimulates collagen synthesis, promotes angiogenesis, and modulates metalloproteinase activity in skin," with significant effects observed in cell culture models at concentrations as low as 1 nanomolar (PubMed).

Clinical studies on topical GHK-Cu for skin aging and wound repair have used formulations ranging from 0.1 to 1 percent. A double-blind study published in Archives of Dermatological Research found that a 1 percent GHK-Cu cream applied twice daily for 12 weeks produced a statistically significant reduction in fine lines and improvement in skin density compared with vehicle control (N=67, P<0.05) (PubMed). Frequency of application is typically twice daily; less frequent application has not been studied in controlled trials.

Serum and gel formulations penetrate more deeply than cream vehicles because of lower molecular weight carriers. GHK-Cu has a molecular weight of 340 Daltons, placing it below the 500-Dalton threshold commonly cited for transdermal absorption (PubMed).

GHK-Cu Injection Dosing

Injectable GHK-Cu is less studied than topical formulations but is used in aesthetic medicine for scalp (hair loss), facial rejuvenation, and wound healing. Doses in published and clinical-protocol literature range from 0.5 to 2 mg per injection site per session.

A 2018 study in the International Journal of Molecular Sciences found that GHK-Cu at 10 to 100 nanomolar concentrations activated 31 anti-aging genes and suppressed 22 pro-inflammatory genes in human fibroblasts, suggesting mechanistic plausibility for tissue repair applications (PubMed).

For scalp injections targeting androgenic alopecia, the typical protocol involves 1 mg GHK-Cu per session, injected intradermally across 10 to 20 sites (0.05 to 0.1 mg per site), once weekly for 8 to 12 weeks. No Phase III randomized controlled trial has validated this specific regimen. The evidence base consists of in vitro data, small pilot studies, and case series.

Reconstitution: a 10 mg GHK-Cu vial dissolved in 5 mL bacteriostatic water yields 2 mg/mL. A 0.1 mg intradermal dose requires drawing 0.05 mL. Precision at this volume requires a 0.3 mL insulin syringe with half-unit markings.

Systemic injection of GHK-Cu at higher doses has not been studied in human clinical trials. Animal toxicity data suggest GHK-Cu is well tolerated at doses up to 100 mg/kg in rodents, but that finding does not establish a human safety ceiling (PubMed).

Stacking BPC-157 and TB-500: Combined Dosing Logic

Combining BPC-157 and TB-500 is common in performance-medicine practice because their proposed mechanisms are complementary. BPC-157 appears to work primarily through upregulation of growth hormone receptor expression and nitric oxide synthesis, while TB-500 promotes actin polymerization and cell migration via its interaction with G-actin (PubMed: Goldstein 2012).

No published human trial has tested the combination. Based on the individual preclinical dose-response data, practitioners typically use:

• BPC-157: 250 to 500 mcg subcutaneously once daily.
• TB-500: 2 to 2.5 mg subcutaneously twice weekly.
• Duration: 4 to 8 weeks for an acute injury; 6 to 12 weeks for chronic tendinopathy.

These can be injected separately or, if the compounding pharmacy validates compatibility, co-mixed in the same syringe. Stability data for the combination do not exist in peer-reviewed literature.

HealthRX Peptide Dosing Decision Framework (Unit Check Protocol)

Before drawing any peptide dose, apply this three-step unit check:

1. Identify the unit on the vial label (mcg or mg). BPC-157 vials are commonly labeled in mg total content but dosed in mcg per injection. TB-500 vials are labeled and dosed in mg.
2. Calculate concentration after reconstitution. Divide total vial content (convert to mcg if needed) by volume of bacteriostatic water added in mL.
3. Cross-check drawn volume against intended dose. If your intended dose in mcg divided by concentration in mcg/mL does not equal the volume on the syringe, do not inject. Recheck the calculation.

This framework catches the majority of unit-transposition errors before they reach the patient.

Regulatory and Safety Context

BPC-157, TB-500, and GHK-Cu have no FDA-approved therapeutic indication as of January 2025 (FDA drug database). All three are available only through compounding pharmacies as research peptides or off-label preparations. The FDA issued a memorandum in 2023 clarifying that BPC-157 cannot be compounded under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act because it is not on the list of bulk substances approved for compounding (FDA 503A bulks list).

Reported adverse effects in animal studies include transient hypotension with high-dose intravenous BPC-157. No controlled human safety trials have been published. The absence of documented serious adverse events in the gray-market literature should not be interpreted as confirmed safety; absence of evidence is not evidence of absence (PubMed: adverse event reporting).

Thymosin Beta-4 is listed by the World Anti-Doping Agency (WADA) under the S2 category (Peptide Hormones, Growth Factors, and Related Substances) as a prohibited substance in sport (WADA Prohibited List 2024). TB-500, as a fragment of TB4, falls under the same prohibition. Athletes subject to WADA testing should not use TB-500 regardless of dose.

Peptide Storage and Reconstitution Quality

Peptide degradation is a silent source of dosing inaccuracy. Even a correctly measured dose delivers sub-therapeutic amounts if the peptide has partially degraded. BPC-157 lyophilized powder stored at minus 20 degrees Celsius retains greater than 95 percent purity for up to 24 months per validated high-performance liquid chromatography (HPLC) assays in published pharmaceutical research (PubMed).

After reconstitution with bacteriostatic water:

• Store at 2 to 8 degrees Celsius (standard refrigerator).
• Use within 28 days.
• Discard if the solution becomes cloudy or shows particulate matter.
• Avoid drawing from the vial with an 18-gauge or larger needle; use a 23- to 25-gauge needle to minimize stopper coring.

GHK-Cu is more stable than BPC-157 post-reconstitution because the copper coordination bond resists hydrolysis. Reconstituted GHK-Cu retains activity for up to 60 days at 4 degrees Celsius in unpublished compounding pharmacy data, though peer-reviewed stability studies are lacking.